Meningococcal vaccines: A progress report

BioDrugs

Volumn 16, Issue 5, 2002, Pages 321-329

  Wildes, Simone S ^a   Tunkel, Allan R ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B TETANUS TOXOID CONJUGATE VACCINE; MENINGOCOCCUS C CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; PENICILLIN G; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; CROSS REACTION; EPIDEMIC; HUMAN; MENINGITIS; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SEPTICEMIA; VACCINATION; ANIMAL; BLOOD; EPIDEMIC MENINGITIS; IMMUNOLOGY; PROGRAM DEVELOPMENT; REVIEW; STATISTICS;

ANIMALS; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PROGRAM DEVELOPMENT;

EID: 0036436754     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200216050-00001     Document Type: Article

References (74)

1. Riedo FX, Plikaytis BD. Broome CV. Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J 1995; 14: 643-57
2. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344: 1378-88
3. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180: 1894-901
4. Moore PS. Meningococcal meningitis in sub-Saharan Africa: A model for the epidemic process. Clin Infect Dis 1992; 14: 515-25
5. Greenwood BM, Bradley AK, Wall RA. Meningococcal disease and season in sub-Saharan Africa. Lancet 1985; II: 829-30
6. Jackson LA, Schuchat A, Reeves MW, et al. Serogroup C meningococcal outbreaks in the United States: An emerging threat. JAMA 1995; 273: 383-9
7. Whalen CM, Hockin JC, Ryan A, et al. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992: Emergence of a virulent clone of Neisseria meningitidis. JAMA 1995; 273: 390-4
8. Berron S, La Fuente LD, Martin E, et al. Increasing incidence of meningococcal disease in Spain associated with a new variant of serogroup C. Eur J Clin Microbiol Infect Dis 1998; 17: 85-9
9. Stephens DS. Uncloaking the meningococcus: Dynamics of carriage and disease. Lancet 1999; 353: 941-2
10. Peltola H. Chemoprophylaxis of bacterial meningitis. Infect Dis Clin North Am 1999; 13: 685-710
11. Imrey PB, Jackson LA. Ludwinski PH, et al. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. Antimicrob Agents Chemother 1995; 33: 3133-7
12. Cookson ST, Corrales JL, Lotero JO, et al. Disco fever: Epidemic meningococcal disease in northeastern Argentina associated with disco patronage. J Infect Dis 1998; 178: 266-9
13. Koh YM, Barnes GH, Kaczmarski E, et al. Outbreak of meningococcal disease linked to a sports club. Lancet 1998: 352: 706-7
14. Cartwright KA, Jones DM, Smith AJ, et al. Influenza A and meningococcal disease. Lancet 1991: 338: 554-7
15. Young LS, Laforce FM, Head JJ, et al. A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med 1972; 287: 5-9
16. Moore PS, Hierholzer J, Dewitt W, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA 1990; 264: 1271-5
17. Fischer M, Hedberg K. Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997; 16: 979-83
18. Yusuf HR, Rochat RW, Baughman WS, et al. Maternal cigarette smoking and invasive meningococcal disease: A cohort study among young children in metropolitan Atlanta, 1989-1996. Am J Public Health 1999; 89: 712-7
19. Blackwell CC, Weir DM, James VS, et al. Secretor status, smoking and carriage of Neisseria meningitidis. Epidemiol Infect 1990; 104: 203-9
20. Ross SC, Densen P. Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 1984; 64: 243-73
21. Petersen BH, Lee TJ, Synderman R, et al. Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7 or C8 deficiency. Ann Intern Med 1979; 90: 917-20
22. Braconier JH, Sjoholm AG, Soderstrom C. Fulminant meningococcal disease infections in a family with inherited deficiency of properdin. Scand J Infect Dis 1983; 15: 339-45
23. Densen P, Weiler JM, Griffiss JM, et al. Familial properdin deficiency and fatal meningococcemia. N Engl J Med 1987; 316: 922-6
24. Francke EL, Neu HC. Postsplenectomy infection. Surg Clin North Am 1981; 61: 135-55
25. van Deuren M, Brandtzaeg P, van der Meet JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000; 13: 144-66
26. Tunkel AR, Scheld WM. Acute bacterial meningitis. Lancet 1995; 346: 1675-80
27. Saez-Nieto JA, Lujan R, Berron S, et al. Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: A 5-year history (1985-1989). Clin Infect Dis 1992; 14: 392-402
28. Campos J, Trujillo G, Seubo T. et al. Discriminative criteria for Neisseria meningitidis isolates that are moderately susceptible to penicillin and ampicillin. Antimicrob Agents Chemother 1992; 36: 1028-31
29. Jackson LA, Tenover FC, Baker C, et al. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. J Infect Dis 1994; 169: 438-41
30. Woods CR, Smith AL, Wasilauskas BL, et al. Invasive disease caused by Neisseria meningitidis relatively resistant to penicillin in North Carolina. J Infect Dis 1994; 170: 453-6
31. Rosenstein NE, Stocker SA, Popovic T, et al. Antimicrobial resistance of Neisseria meningitidis in the United States, 1997. Clin Infect Dis 2000; 30: 212-3
32. Oppenheim BA. Antibiotic resistance in Neisseria meningitidis. Clin Infect Dis 1997; 24 Suppl. 1: S98-101
33. Casado-Flores J, Osona B, Comingo P, et al. Meningococcal meningitis during penicillin therapy for meningococcemia [case report]. Clin Infect Dis 1997; 25: 1479
34. Goldani LZ. Inducement of Neisseria meningitidis resistance to ampicillin and penicillin in a patient with meningococcemia treated with high doses of ampicillin [case report]. Clin Infect Dis 1998; 26: 772
35. Cubells CL, Garcia JG, Martinez JR, et al. Clinical data in children with meningococcal meningitis in a Spanish hospital. Acta Paediatr 1997; 86: 26-9
36. Shaw WV. Chloramphenicol resistance in meningococci. N Engl J Med 1998; 339: 917-8
37. Galimand M, Gerbaud G, Guibourdenche M, et al. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl J Med 1998; 339: 868-74
38. Centers for Disease Control and Prevention. Control and prevention of meningococcal disease and control and prevention of serogroup C meningococcal disease: Evaluation and management of suspected outbreaks. MMWR Morb Mortal Wkly Rep 1997; 46: 1-11
39. Jones GR, Williams JN, Christodoulides M, et al. Lack of immunity in university students before an outbreak of serogroup C meningococcal infection. J Infect Dis 2000; 181: 1172-5
40. Pollard AJ, Levin M. Vaccines for the prevention of meningococcal diseases. Pediatr Infect Dis J 2000; 19: 33-45
41. Peltola H, Makela PH, Kayhty H, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977; 297: 686-91
42. Goldscneider I, Lepow ML, Golschlich EC, et al. Immunogenicity of Group A and group C meningococcal polysaccharide in human infants. J Infect Dis 1973; 128: 769-76
43. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; 2: 114-8
44. Lieberman JM, Chiu SS, Wong VK, et al. Safety and immunogenicity of serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccines in young children: A randomized controlled trial. JAMA 1996; 275: 1499-503
45. Zangwill KM, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccine in US Air Force personnel. J Infect Dis 1994; 169: 847-52
46. Robbins JB, Towne DW, Gotschlich EC, et al. "Love's Labours Lost": Failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet 1997; 350: 880-2
47. de Wals P, de Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285: 177-81
48. Rosenstein N, Levine O, Taylor JP, et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 1998; 279: 435-9
49. Harrison LH. Preventing meningococcal infection in college students. Clin Infect Dis 2000; 30: 648-51
50. American Academy of Pediatrics, Committee on Infectious Diseases. Meningococcal disease prevention and control strategies for practice-based physicians (addendum: recommendations for college students). Pediatrics 2000; 106: 1500-4
51. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183: 160-3
52. MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants. JAMA 2000; 283: 2795-801
53. Campagne G, Garba A, Fabre P, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000; 19: 144-50
54. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J 2001; 20: 153-9
55. Public Health Laboratory Service. Vaccination programme for group C meningococcal infection is launched. Commun Dis Rep CDR Weekly 1999; 9: 261-4
56. Maiden MCJ, Spratt BG. Meningococcal conjugate vaccine: New opportunities and new challenges. Lancet 1999; 354: 615-6
57. Ramsay ME, Andrews N, Kaczmarski EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357: 195-6
58. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: A success story. Vaccine 2001; 20: S58-67
59. PHLS Communicable Disease Surveillance Centre. Meningitis C Vaccine to be Offered to 20 to 24 Year Olds [Online]. Available from URL: http://www.phls.org.uk [Accessed 2002 Sep 26]
60. Perkins BA. New opportunities for the prevention of meningococcal disease. JAMA 2000; 283: 2842-3
61. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000; 181: 761-4
62. Borrow R, Goldblatt D, Andrews N, et al. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 2001; 184: 377-80
63. An Advisory Committee statement (ACS). Statement on recommended use of meningococcal vaccines. Can Commun Dis Rep 2001; 27: 2-36
64. Edwards KM, Decker MD. Combination vaccines. Infect Dis Clin North Am 2001; 15: 209-30
65. Sierra GVG, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14: 195-207
66. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338: 1093-6
67. Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: Comparison with efficacy. Infect Immun 1994; 62: 4419-24
68. Boslego JB, Garcia J, Cruz C. Efficacy, safety, and immunogenicity of a meningococcal vaccine group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 1995; 13: 821-9
69. De Moraes JC, Perkins BA. Camargo MCC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340: 1074-8
70. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile. JAMA 1999; 281: 1520-7
71. Wenger JD. Serogroup B meningococcal disease: New outbreaks, new strategies. JAMA 1999; 281: 1541-3
72. de Kleijn ED, de Groot R, Labadie J, et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children 2-3 and 7-8 years of age. Vaccine 2000; 18: 1456-66
73. de Kleijn ED, de Groot R, Lafeber AB, et al. Prevention of meningococcal serogroup B infections in children: A protein-based vaccine induces immunologic memory. J Infect Dis 2001; 184: 98-102
74. Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. Infect Dis Clin North Am 2001; 15: 155-69